Cash conversion remains highly erratic, highlighted by a 2025Q1 OCF/NI ratio of -12.92 and free cash flow margins that swung from -25.4% to 25.7% within a single year.
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Cash from Operations | 2.3B | 1.16B | 1.7B | 2.31B | -181.82M | 1.93B | 2.64B | 2.27B | 1.78B | 1.87B | 1.9B | 1.17B | 1.3B | 1.14B | 2.2B | 566M | 2.16B | 1.54B | 1.5B | 1.37B | 853.92M | 2.09B | 2.69B | 1.99B | 2.23B | 1.25B | 3B | 1.92B | 2.22B | 3.46B | 1.22B |
| Operating CF Margin % | - | 6.52% | 9.42% | 12.71% | -1.02% | 11.23% | 15.25% | 13.26% | 9.82% | 10.52% | 7.77% | 4.81% | 6.09% | 4.88% | 8.87% | 2.51% | 8.48% | 6.66% | 5.67% | 5.1% | 3.17% | 6.88% | 8.89% | 6.86% | 7% | 3.86% | 7.91% | 6.08% | 7.33% | 10.1% | 3.81% |
| Operating CF Growth % | 454.29% | -31.53% | -26.51% | 1370.09% | -109.44% | -27.02% | 16.14% | 27.71% | -4.81% | -1.79% | 63.15% | -10.44% | 14.5% | -48.23% | 288.34% | -73.75% | 39.55% | 3.34% | 9.26% | 60.24% | -59.12% | -22.49% | 35.53% | -10.84% | 78.43% | -58.41% | 56.58% | -13.5% | -35.95% | 184.54% | 0.24% |
| Net Income | 972.48M | 895M | -912.95M | -492.99M | -1.7B | 718.64M | 1.19B | 1.33B | 1.31B | 1.03B | 1.07B | 414M | 221M | 1.17B | 262M | -776M | 1.45B | 410M | 8M | 4.17B | 5.38B | 2.95B | 2.83B | 693.98M | -3.21B | -2.61B | 9.63B | 1.8B | 6.02B | 2.57B | -272.38M |
| Depreciation & Amortization | 1.12B | 1.13B | 1.26B | 1.39B | 1.26B | 1.24B | 1.46B | 1.09B | 1.09B | 1.02B | 1.27B | 1.28B | 1.19B | 1.35B | 1.43B | 1.46B | 1.42B | 1.47B | 1.19B | 852.54M | 834.22M | 1.51B | 2.29B | 2.01B | 2.19B | 2.8B | 2.33B | 1.86B | 1.88B | 1.68B | 1.66B |
| Stock-Based Compensation | 94M | 141M | 0 | 0 | 0 | 0 | 112M | 0 | 102M | 122M | 95M | 82M | 85M | 104M | 80M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Taxes | 95M | 0 | 0 | 0 | 0 | 0 | 284M | 0 | 193M | 349M | 327M | 239M | 26M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 488.23M | 330M | 1.35B | -98.38M | 1.5B | 143.02M | 131M | 609.99M | 962M | 1.46B | 1.25B | 382M | 10M | -258M | -1.17B | 1.35B | -291M | -112M | 12M | -393.52M | -5.74B | -1.9B | -2.43B | -197.26M | 2.69B | 561.96M | -7.75B | -1.15B | -5.82B | -1.06B | 0 |
| Working Capital Changes | -472.98M | -1.33B | 7.57M | 1.51B | -1.24B | -179.66M | -536M | -755.49M | -500M | -509M | -512M | -346M | 540M | -1.69B | 392M | -1.17B | -509M | -222M | 285M | -851.16M | -1.38B | -364.74M | -32.46M | -90.52M | 565.11M | 494.52M | -1.2B | -590.31M | 138.13M | 168.18M | -81.15M |
| Change in Receivables | -20.18M | -9M | -1.08M | 322.17M | -359.43M | 0 | 92M | 0 | -97M | 64M | 357M | -554M | 584M | -2.1B | 210M | -1.35B | 0 | -479M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | -96.72M | -115M | 248.79M | 277.85M | -601.16M | -686.73M | -578M | -195.87M | -394M | -144M | 44M | 22M | -77M | -165M | -19M | -81M | -705M | 687M | 41M | -389.57M | 2.27M | -195.88M | 0 | 0 | 0 | 0 | -981.69M | 45.71M | -59.69M | -213.64M | 0 |
| Change in Payables | -133.89M | 0 | -630.63M | 387.04M | 54.65M | 258.85M | 0 | -413M | 0 | 0 | -154M | 464M | -607M | 769M | -233M | 755M | 0 | -479M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Investing | -991.68M | -737M | -633.87M | -553.53M | -1.58B | -317.95M | -1.27B | -702.89M | -1.49B | -3.2B | -1.17B | -1.94B | -984M | -997M | -912M | -1.46B | -702M | -219M | -3.1B | 3.97B | 3.79B | 1.3B | 652.85M | 740.83M | -247.77M | -4.57B | -2.41B | -3.84B | 3.69B | -60.91M | -2.08B |
| Capital Expenditures | -475.68M | -269M | -731.22M | -695.16M | -847.09M | -901.85M | -895M | -1.13B | -843M | -859M | -869M | -957M | -846M | -993M | -1.06B | -841M | -952M | -620M | -892M | -780.52M | -803.15M | -996.29M | -1.39B | -978.24M | -1.16B | -2.15B | -3.18B | -1.67B | -1.62B | -1.67B | -2.32B |
| CapEx % of Revenue | 2.69% | 1.51% | 4.06% | 3.83% | 4.75% | 5.26% | 5.17% | 6.61% | 4.65% | 4.83% | 3.54% | 3.95% | 3.95% | 4.26% | 4.28% | 3.72% | 3.75% | 2.67% | 3.38% | 2.91% | 2.98% | 3.28% | 4.58% | 3.37% | 3.65% | 6.63% | 8.37% | 5.28% | 5.36% | 4.88% | 7.26% |
| Acquisitions | -223.58M | -3M | 141.7M | 104.87M | -600.11M | -3.5B | -313M | -82.82M | -558M | -2.28B | -171M | -1.06B | -197M | 68M | -226M | -509M | -106M | -210M | -5.29B | 155.01M | -2.15B | -1.19B | -439.66M | -468.48M | -626.1M | -3.64B | -3.22B | -3B | -862.04M | -302.73M | -456.37M |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -198M | -465M | 27.04M | 134.06M | -12.61M | 4.02B | 20M | -27.98M | -549M | -463M | -1.11B | 516M | -147M | -430M | -196M | 2M | 129M | -101M | -3.12B | 4.56B | 3.78B | 2.25B | -1.18B | 2.38B | 1.54B | 240.52M | -638.84M | -251.43M | 1.04B | 1.81B | 695.81M |
| Cash from Financing | 132.62M | 107M | -536.52M | -916.79M | 525.49M | -2.77B | 483M | -1.86B | -1.19B | 55M | -420M | 508M | -1.19B | -1.24B | -292M | -1.79B | -96M | -545M | -3.58B | -2.37B | -3.71B | -2.59B | -2.14B | -1.35B | -897.7M | 3.16B | -2.04B | -2.61B | -809.17M | -2.64B | 674.11M |
| Debt Issued (Net) | 475.44M | 448M | -88.7M | -195.68M | 1.15B | -296.68M | 767M | 122M | 126M | -217M | -1.61B | 1.25B | -264M | -122M | 730M | -860M | 134M | 60M | 380M | -281.89M | -437.19M | -323.37M | -1.67B | -941.72M | -419.31M | 3.96B | 613.29M | -719.5M | -445.09M | -2.25B | 1.01B |
| Equity Issued (Net) | 20.89M | 0 | -444.57M | -715.7M | -183.92M | -1.91B | -343M | -1.48B | -1.04B | -642M | -526M | -506M | -596M | -562M | -768M | -671M | 65M | 29M | -3.26B | -1.45B | -2.75B | -1.76B | -17.7M | 49.23M | -19.06M | -336.05M | -579.22M | -37.76M | -156.89M | -112.73M | 35.35M |
| Dividends Paid | -328M | -328M | -1.08M | -2.16M | -433M | -569.71M | -1M | -507.02M | -401M | -384M | -330M | -298M | -292M | -272M | -255M | -259M | -296M | -634M | -698M | -639.92M | -522.81M | -503.21M | -459.57M | -458.95M | -459.33M | -458.56M | -400.34M | -361.74M | -324.86M | -250M | -253.09M |
| Share Repurchases | 0 | 0 | -444.57M | -715.7M | -196.53M | -1.93B | -343M | -1.54B | -1.04B | -642M | -606M | -506M | -713M | -669M | -768M | 0 | 0 | 0 | -3.26B | -1.45B | -2.75B | -1.76B | -17.7M | 0 | -19.06M | -336.05M | -579.22M | -37.76M | -156.89M | -112.73M | 0 |
| Other Financing | -35.71M | -13M | -2.16M | -3.24M | -6.31M | -2.36M | 60M | -2.24M | 125M | 1.3B | 2.98B | 81M | -37M | -285M | 0 | 3M | 1M | 0 | 0 | -639.23M | -522.81M | -844.31K | -459.57M | -1.59M | 0 | 0 | -1.68B | -1.49B | 111.7M | -14.55M | 0 |
| Net Change in Cash | 1.34B | 393M | 421.64M | 813.77M | -1.37B | -1.33B | 1.8B | -330.07M | -251M | -395M | 568M | -107M | -592M | -1.37B | 687M | -2.69B | 1.45B | 766M | -5.26B | 2.86B | 729.66M | 958.29M | 1.28B | 1.21B | 968.22M | -200.06M | -1.24B | -4.23B | 5.13B | 730M | -237.83M |
| Free Cash Flow | 1.91B | 893M | 1.35B | 1.94B | -648.45M | 1.46B | 2.15B | 1.69B | 937M | 1.01B | 1.03B | 210M | 457M | 145M | 1.14B | -275M | 1.2B | 925M | 603M | 587.79M | 50.77M | 1.09B | 1.31B | 1.01B | 1.07B | -896.88M | -174.62M | 252.42M | 594.3M | 1.79B | -1.1B |
| FCF Margin % | 10.8% | 5.01% | 7.51% | 10.66% | -3.64% | 8.49% | 12.45% | 9.88% | 5.17% | 5.69% | 4.22% | 0.87% | 2.14% | 0.62% | 4.59% | -1.22% | 4.74% | 3.99% | 2.29% | 2.19% | 0.19% | 3.6% | 4.31% | 3.48% | 3.35% | -2.77% | -0.46% | 0.8% | 1.96% | 5.21% | -3.44% |
| FCF Growth % | 272.27% | -34.06% | -30.1% | 398.77% | -144.49% | -32.37% | 27.26% | 80.73% | -7.32% | -2.32% | 392.86% | -54.05% | 215.17% | -87.25% | 513.45% | -122.84% | 30.16% | 53.4% | 2.59% | 1057.86% | -95.35% | -16.37% | 29.35% | -5.45% | 219.11% | -413.63% | -169.18% | -57.53% | -66.78% | 262.77% | 5.52% |
| FCF per Share | 1.97 | 0.93 | 1.45 | 2.04 | -0.68 | 1.53 | 2.25 | 1.74 | 0.94 | 1.00 | 1.05 | 0.21 | 0.46 | 0.15 | 1.15 | -0.27 | 1.19 | 0.93 | 0.57 | 0.50 | 0.04 | 0.82 | 0.95 | 0.74 | 0.79 | -0.66 | -0.12 | 0.18 | 0.43 | 1.31 | -0.78 |
| FCF Conversion (FCF/Net Income) | 1.97x | 1.30x | -2.42x | -4.96x | 0.11x | 0.58x | 2.22x | 1.95x | 1.63x | 1.13x | 1.31x | 1.81x | 3.14x | 0.97x | 9.73x | -0.44x | 1.49x | 3.77x | -16.25x | 0.33x | 0.16x | 0.73x | 0.95x | 2.87x | -0.69x | -0.48x | 0.31x | 1.06x | 0.37x | 1.35x | -4.47x |
| Interest Paid | 104M | 253M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Litigation and regulatory volatility
As reported in recent financial filings, the relationship between net income and operating cash flow is erratic, highlighted by a 2025Q1 OCF/NI ratio of -12.92, which suggests that accounting profits are frequently decoupled from the actual cash generation capabilities of the underlying medical device business operations.
The extreme variance in conversion ratios indicates that non-cash charges and significant working capital swings are masking the true cash-generating capacity of the firm. Investors should monitor whether these discrepancies are purely related to one-time litigation settlements or if they reflect a structural inability to convert reported earnings into tangible liquidity.
Based on the provided cash flow data, free cash flow margins have fluctuated wildly from a -25.4% trough in 2025Q1 to a 25.7% peak in 2025Q4, indicating that the company's ability to sustain positive cash flow remains highly sensitive to non-recurring operational and legal expenses.
The lack of a consistent FCF growth trend suggests that the business is currently in a defensive posture rather than a value-creation phase. The volatility in these margins implies that the company's cash flow profile is currently dictated more by external remediation costs than by core product performance.
According to historical cash flow statements, working capital changes have been a major source of volatility, including a massive $1.4 billion outflow in 2025Q1, which suggests that inventory management and collection cycles are currently subject to significant, unpredictable disruptions that impact the firm's immediate liquidity position.
These large swings in working capital often point to difficulties in managing supply chain inventory or delays in receiving payments from hospital systems. Such instability warrants further investigation into whether these are temporary timing differences or evidence of deeper inefficiencies in the company's order-to-cash cycle.
As evidenced by the company's reported figures, capital expenditures have consistently consumed a significant portion of revenue, with CapEx/Rev ratios frequently exceeding 4%, which indicates that the firm must maintain high levels of reinvestment just to sustain its existing medical imaging and diagnostic hardware installed base.
The persistent need for high capital intensity suggests that the company is struggling to transition toward a less asset-heavy, software-driven model. This level of spending may limit the firm's ability to deleverage or return capital to shareholders until the core product portfolio reaches a more stable, mature state.
Quick answers to the most common questions about buying PHG stock.
Koninklijke Philips N.V. (PHG) generated $1.16B in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Koninklijke Philips N.V. (PHG) generated $893.0M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Koninklijke Philips N.V. (PHG) spent $269.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Koninklijke Philips N.V. (PHG) returned $328.0M to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.